Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

PF-04958242

Generic Name: PF-04958242

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₀N_₂O_₄S_₂

CAS Number: 1258963-59-5

Unique Ingredient Identifier: 9G1A824CC2

Overview

PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing Loss, Sensorineural.

Background

PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing Loss, Sensorineural.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Phase 1

Completed

Posted: 2021/12/08

Sponsor:Biogen

ID:NCT05148481

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Phase 1

Completed

Posted: 2019/09/06

Sponsor:Biogen

ID:NCT04079101

A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants

Phase 1

Completed

Posted: 2019/08/28

Sponsor:Biogen

ID:NCT04068532

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

Phase 2

Completed

Posted: 2018/11/19

Sponsor:Biogen

ID:NCT03745820

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Phase 2

Terminated

Posted: 2016/08/04

Sponsor:Biogen

ID:NCT02855411

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy